Search for European Projects

30 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH)

Start date: Jun 1, 2015, End date: Nov 30, 2020,

The problem: finding the right patient for the right treatmentDespite a large and growing disease burden in osteoarthritis (OA), many pharmaceutical companies have de-emphasized or even abandoned OA drug development due to perceived hurdles. Crucial in this is the lack of appropriate outcome measures that can robustly identify patient benefit from a specific therapy. The lack of specific and sensi ...
Read Project

 25

 FINISHED 

European AIDS Vaccine Initiative 2020 (EAVI2020)

Start date: Nov 1, 2015, End date: Oct 31, 2020,

HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradicati ...
Read Project

 27

 FINISHED 

Sorting of Self (SOS)

Start date: May 1, 2015, End date: Apr 30, 2020,

During inflammation and infection, we are simultaneously confronted with both self and non-self in form of dying cells and microbes, respectively. Mechanisms that facilitate the non-immunogenic clearance of self-antigens derived from apoptotic and necrotic cells and that, in parallel, allow the initiation of an immune response against invading pathogens are incompletely understood. Recent data fro ...
Read Project

 1

 FINISHED 

Pathogen and Graphene (PANG)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

Complications related to infectious diseases have significantly reduced, particularly in the developed countries, due to the availability and use of broad-range antibiotics and wide variety of antimicrobial agents. Excessive use of antibiotics and antimicrobial agents increased significantly the number of multi-drug resistant (MDR) bacteria. This has resulted in a serious threat to public health. ...
Read Project

 8

 FINISHED 

Reactive oxygen species (ROS) as Elixirs against chronic Disease: OXidative regulatory mechanisms In T cells and neutrophils. (REDOXIT)

Start date: Jul 1, 2015, End date: Jun 30, 2019,

We are proposing a four-year programme of knowledge transfer and networking between Aston University (ASTON, UK), Universitatsklinikum Erlangen (UKER, Germany) and Redoxis AB (Redoxis, Sweden). Our proposal targets an emerging area of biology, i.e. reactive oxygen species (ROS)-mediated regulation of immune responses; it brings together the application of small molecule candidate drugs to generate ...
Read Project

 3

 FINISHED 

Clonidine for Sedation of Paediatric Patients in the Intensive Care Unit (CloSed)

Start date: Dec 1, 2013, End date: Nov 30, 2018,

The majority of critically ill children admitted to Paediatric Intensive Care Units (PICU) will require sedation and analgesia which is commonly achieved with a combination of an benzodiazepine and an opioid. However, these agents have a significant side-effect profile, including tolerance, withdrawal and respiratory/circulatory depression. Clonidine is commonly used for sedation in PICU and recom ...
Read Project

 10

 FINISHED 

PanCare Studies in Fertility and Ototoxicity to Improve Quality of Life after Cancer during Childhood, Adolescence and Young Adulthood (PANCARELIFE)

Start date: Nov 1, 2013, End date: Oct 31, 2018,

Survival rates after childhood cancer now reach nearly 80% in developed European countries as a result of more effective therapies and better supportive care, leading to a steady increase in the number of survivors in the population. However, the treatments that have improved survival are harsh and cause serious side-effects that can greatly impact survivors’ quality of life in the long term. The ...
Read Project

 19

 FINISHED 

Development and Epilepsy - Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult to treat Epilepsy (DESIRE)

Start date: Oct 1, 2013, End date: Sep 30, 2018,

DESIRE will focus on epileptogenic developmental disorders EDD, i.e. early onset epilepsies whose origin is closely related to developmental brain processes. A major cause of EDD are malformations of cortical development (MCD), either macroscopic or subtle. EDD are often manifested as epileptic encephalopathies (EE), i.e. conditions in which epileptic activity itself may contribute to severe cogni ...
Read Project

 29

 FINISHED 

EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma (EEC)

Start date: Oct 1, 2013, End date: Sep 30, 2018,

Ewing Sarcomas (ES) are fatal, rare bone cancers particularly affecting young people. About 60% of patients achieve long term survival with current treatment but there has been no improvement in this proportion for 25 years. Treatment is unsuccessful because chemotherapy fails to prevent the development of, or to effectively treat established, metastases. In addition, of the 600 new cases of ES o ...
Read Project

 21

 FINISHED 

MicroRNAs in the Pathogenesis, Treatment and Prevention of Epilepsy (EPIMIRNA)

Start date: Sep 1, 2013, End date: Aug 31, 2018,

Epilepsy is a major burden for patients and health systems worldwide. It is a common chronic neurological disorder affecting people of all ages, and the shortfall in existing treatments means that 30% of patients continue to suffer uncontrolled seizures. MicroRNAs (miRNA) are a recently-discovered, network-level layer of gene expression regulation that controls protein levels of entire signaling p ...
Read Project

 19

 FINISHED 

ORganizational Behaviour improvement for Energy Efficient adminisTrative public offices (OrbEEt)

Start date: Mar 1, 2015, End date: Feb 28, 2018,

Tertiary sector buildings sector consume a sizeable proportion of EU total energy consumption and the majority of consumption is directly attributed to the operational phase of the building life-cycle. Occupant behaviour is a major cause of this consumption. OrbEEt proposes an ICT-based framework to induce behaviour change toward energy efficiency by transforming energy measurements into personali ...
Read Project

 10

 FINISHED 

Nanomedicine for target-specific imaging and treatment of atherosclerosis: development and initial clinical feasibility (NanoAthero)

Start date: Feb 1, 2013, End date: Jan 31, 2018,

NanoAthero aims to have demonstration of initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have proven safety records, and strong preliminary in vitro and in vivo proofs of efficacy are available. Partners have patented ...
Read Project

 17

 FINISHED 

European Medical Information Framework (EMIF)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Read Project

 64

 FINISHED 

GAbapentin in Paediatric Pain (GAPP)

Start date: Jul 1, 2013, End date: Jun 30, 2017,

Chronic pain is estimated to affect 15-20% of children with varying disabilities. Due to the paucity of clinical information and appropriate medicinal products, in clinical practice paediatric patients are often under-treated causing profound impact on their QoL.To date, opioids, non-steroid anti-inflammatory drugs (NSAIDs), antidepressants and anticonvulsants are used to treat pain, but only few ...
Read Project

 16

 FINISHED 

Open Project for the European Radiation Research Area (OPERRA)

Start date: Jun 1, 2013, End date: May 31, 2017,

"Within the OPERRA project, it is proposed that the MELODI Association, as a well-advanced network, takes the lead in establishing the necessary structures able to manage the long-term European research programmes in radiation protection, also taking advantage of the valuable experience gathered through the DoReMi network of excellence. Whilst in fields adjacent to low-dose risk research (radioeco ...
Read Project

 71

 FINISHED 

BeTheCuRE (BTCURE)

Start date: Apr 1, 2011, End date: Mar 31, 2017,

BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that ...
Read Project

 41

 FINISHED 

European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke (EuroHYP-1)

Start date: Feb 1, 2012, End date: Jan 31, 2017,

The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke.Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so it ...
Read Project

 38

 FINISHED 

Towards Early diagnosis and biomarker validation in Arthritis Management (EURO-TEAM)

Start date: Nov 1, 2012, End date: Oct 31, 2016,

An ideal intervention in a chronic inflammatory disease such as Rheumatoid Arthritis (RA) would be a preventive one. In order to develop preventive strategies and therapies two key developments need to occur: (1) Biomarkers need to be identified that can be used to predict an individual’s risk of developing RA. (2) Modifiable disease mechanisms need to be identified and characterized in the early ...
Read Project

 17

 FINISHED 

DEferiprone Evaluation in Paediatrics (DEEP)

Start date: Jan 1, 2011, End date: Aug 31, 2016,

"β-thalassaemia major is one of the most severe forms of chronic congenital anaemia. The recommended treatment consists in regular blood transfusions combined with chelating therapy to remove harmful iron accumulation in the body. The use of deferoxamine, the first chelating agent only available for subcutaneous administration is limited due to toxicity and the lack of compliance, despite its sat ...
Read Project

 18

 FINISHED 

OSTEOIMMUNE - Unraveling the Interactions between the Immune System and Bone (OSTEOIMMUNE)

Start date: Jun 1, 2012, End date: May 31, 2016,

Inflammatory rheumatic diseases affect millions of European citizens causing chronic pain, disability and premature death. Curative treatments are lacking. Conventional research often focuses on one single organ system such as the bone or the immune system and. ignores interactions between organ systems. OSTEOIMMUNE is a supra-disciplinary training network that targets this gap by providing compre ...
Read Project

 12

 FINISHED 

Post-infectious immune reprogramming and its association with persistence and chronicity of respiratory allergic diseases (PreDicta)

Start date: Oct 1, 2010, End date: Mar 31, 2016,

Chronic inflammatory diseases associated with allergy, including asthma and rhinitis, constitute a major and continuously growing public health concern for Europe. However, the causative factors and mechanisms converting a physiological inflammatory reaction to a chronic response triggering allergic disease remain elusive.Viral infections, particularly those caused by human rhinoviruses (RV) are t ...
Read Project

 13

 FINISHED 

Low Dose Research towards Multidisciplinary Integration (DOREMI)

Start date: Jan 1, 2010, End date: Dec 31, 2015,

The aim of DoReMi is to promote the sustainable integration of low dose risk research in Europe in order to aid the effective resolution of the key policy questions identified by the High Level Expert Group (HLEG) on Low Dose Risk Research (www.hleg.de). DoReMi provides an operational tool for the development of the proposed MELODI platform (Multidisciplinary European Low Dose Risk Re-search Initi ...
Read Project

 39

 FINISHED 

Systems biology towards novel chronic kidney disease diagnosis and treatment (SysKID)

Start date: Jan 1, 2010, End date: Dec 31, 2014,

Chronic kidney disease (CKD) affects up to 10% of the population. Besides eventual progression towards end stage renal disease CKD impacts the patient’s quality of life by causing serious comorbidities including cardiovascular complications and bone metabolism disorders. On the everyday clinical level early stage diagnosis and tailored treatment of CKD are still inadequate. In addition, CKD seems ...
Read Project

 30

 FINISHED 

Intelligent Knowledge Platform for Personal Health Monitoring Services (eHealthMonitor)

Start date: Dec 1, 2011, End date: Nov 30, 2014,

The eHealthMonitor project provides a platform that generates a Personal eHealth Knowledge Space (PeKS) as an aggregation of all knowledge sources (e.g., EHR and PHR) relevant for the provision of individualized personal eHealth services. This is realised by integrating service-oriented architecture, knowledge engineering, multiagent systems, and wearable/portable devices technologies. Innovations ...
Read Project

 11

 FINISHED 

Persistence of allergic sensitization (PAS)

Start date: Dec 1, 2009, End date: Nov 30, 2014,

"Allergic disorders are dramatically increasing in the western world over the past several years. Allergies are inappropriate immune responses directed against harmless environmental antigens. Upon primary allergen encounter B cells are induced to differentiate into IgE producing plasma cells. Mast cells and basophils are then sensitized by binding of allergen-specific IgE molecules to the high-af ...
Read Project

 2

 FINISHED 

Influence of protein prenylation and its modulation on the immune system (Pren-IBD)

Start date: Aug 1, 2012, End date: Jul 31, 2014,

Prenylation is a postranslational process leading to changes in protein structure due to the incorporation of a lipidic moiety that significantly modifies their physicochemical properties and their behaviour. Prenylation is therefore a crucial step for key cell processes, such as interaction between proteins, cell and differentiation, cytoskeletal function and vesicular trafficking. The modificati ...
Read Project

 1

 FINISHED 

ADIPOSE DERIVED STROMAL CELLS FOR OSTEOARTHRITIS (ADIPOA)

Start date: Jan 1, 2010, End date: Jun 30, 2014,

Osteoarthritis (OA) is a degenerative joint disease for which no efficient therapy is available. The ADIPOA consortium has previously shown that intraarticular injections of stromal cells prevents OA in two different models, but the mechanisms of this chondroprotective effect remains unknown, and the activation of cartilage derived endogenous stem cells is suspected. The participants have experien ...
Read Project

 12

 FINISHED 

Discovery and preclinical development of new generation tuberculosis vaccines (NEWTBVAC)

Start date: Jan 1, 2010, End date: Feb 28, 2014,

"With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current ...
Read Project

 39

 FINISHED 

European Network for Cell Imaging and Tracking Expertise (ENCITE)

Start date: Jun 1, 2008, End date: Nov 30, 2012,

"Cell therapy can be defined as the transplantation of living cells for the treatment of medical disorders. Three different principles underlie the increasing interest in cell therapy. 1. Transplanted cells used as an “active drug” 2. Transplanted cells used to replace damaged and degenerated tissue. 3. Cells used as a drug delivery vehicle. Promising results have been obtained in pre-clinical and ...
Read Project

 30

 FINISHED 

Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer (GENINCA)

Start date: Jan 1, 2008, End date: Jun 30, 2011,

"GENINCA will address two tumor entities, for which we have good access to pre-malignant lesions and in which genomic instability is a common feature: colorectal and liver cancer. Colorectal cancer amounts to 13.2% of all incident cases of cancer, the second most common form of cancer, surpassed only by lung cancer (13.3%). Liver cancer accounts for about 2% of total cancers, however, the most com ...
Read Project

 14